Has Maxwell Levy received payments from drug or device companies?

Yes. Drug and device makers reported $2,033 in general payments to Maxwell Levy across 70 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Maxwell Levy did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Maxwell Levy come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Maxwell Levy

Neurology · New Orleans, LANPI 1336535327

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.2% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Argenx US, Inc. at 30.1% of the total. 2025 is the largest year on record at $877, 6.5 times the $134 reported in 2020. That places this record below the midpoint for neurology clinicians in LA, where the typical reported total is $2,263.

$2,033in general payments, 2019–2025

Across 70 payments — averaging $29.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Argenx US, Inc.$611
UCB, Inc.$500
AbbVie$351
CSL Behring$124
Jazz Pharmaceuticals Inc.$106
AstraZeneca$89
plus $253 from 8 others

$8,800in research payments, 2019–2025

Across 4 payments — averaging $2200.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Alnylam Pharmaceuticals Inc.$9K

What the payments were for

Speaking & faculty fees$20010%
Food & beverage$1,83390%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Argenx US, Inc.	19	$611
UCB, Inc.	14	$500
AbbVie	16	$351
CSL Behring	2	$124
Jazz Pharmaceuticals Inc.	4	$106
AstraZeneca(2 entities)	2	$89
Johnson & Johnson	3	$70
Neurelis, Inc.	2	$45
Xeris Pharmaceuticals, Inc.	2	$42
Genentech USA, Inc.	2	$34
Lundbeck LLC	1	$18
Boston Scientific	1	$16
Alnylam Pharmaceuticals Inc.	1	$14
Eisai Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VYVGART$240
Zilbrysq$200

How this compares

$2,033 in reported general payments places this provider in the 45th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana →

Medicare billing

Part B allowed, 2024

$20,673

Medicare patients

103

Services billed

198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
LamictalLamotrigine	11	$8,723
Aimovig AutoinjectorErenumab-Aooe	11	$7,953
Lacosamide	14	$2,171
Riluzole	17	$1,203
Pyridostigmine Bromide	33	$1,172
Levetiracetam	33	$1,171
Mycophenolate Mofetil	16	$1,019
Divalproex Sodium	11	$815
Clonazepam	22	$612
Duloxetine Hcl	19	$298
Pregabalin	14	$294
Glycopyrrolate	13	$270
Azathioprine	11	$199
Gabapentin	20	$183
Prednisone	15	$129

Paid to pharmacies, not to this prescriber.

Other neurology in New Orleans

John EnglandNew Orleans$268K
Brian CopelandNew Orleans$211K
Bridget BagertNew Orleans$198K
Sheryl Martin-SchildNew Orleans$106K
Piotr OlejniczakNew Orleans$82K
Elizabeth CrabtreeNew Orleans$36K
Caroline GoldinNew Orleans$36K
Jesus LoveraNew Orleans$27K
Julia StaischNew Orleans$22K
Pooja Mohan RaoNew Orleans$17K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →